



## Brief communication

# Minimum infectious dose for chikungunya virus in *Aedes aegypti* and *Ae. albopictus* mosquitoes

Jeremy P. Ledermann,<sup>1</sup> Erin M. Borland,<sup>1</sup> and Ann M. Powers<sup>1</sup>

## Suggested citation

Ledermann JP, Borland EM, Powers AM. Minimum infectious dose for chikungunya virus in *Aedes aegypti* and *Ae. albopictus* mosquitoes. Rev Panam Salud Publica. 2017;41:e65.

## ABSTRACT

Understanding the ability of the chikungunya virus (CHIKV) to be transmitted by *Aedes* vectors in the Americas is critical for assessing epidemiological risk. One element that must be considered is the minimum infectious dose of virus that can lead to transmission following the extrinsic incubation period. This study aimed to determine the minimum infection rate for the two *Aedes* species studied. The results revealed that doses as low as  $3.9 \log_{10}$  plaque-forming units per mL (pfu/mL) of an Asian genotype CHIKV strain can lead to transmission by *Ae. albopictus*, and doses of at least  $5.3 \log_{10}$  pfu/mL from the same strain are needed for transmission from *Ae. aegypti*. These low infecting doses suggest that infected individuals may be infectious for almost the entire period of their viremia, and therefore, to prevent further cases, measures should be taken to prevent them from getting bitten by mosquitoes during this period.

## Keywords

*Aedes*; chikungunya virus; epidemiology; Americas.

Chikungunya virus (CHIKV) is a positive-sense single-stranded RNA alphavirus belonging to the family *Togaviridae* that has been the focus of a global epidemic beginning in 2004 in coastal Kenya with spread to the Americas in 2013. The virus is responsible for more than 3 million cases of debilitating arthralgia in many countries in the tropics and subtropics over the past decade. Interestingly, there have been multiple genotypes

of CHIKV involved in the global spread of the virus during this time. In Kenya, in 2004, a strain of the East/Central/South African (ECSA) genotype caused two outbreaks in the eastern coastal areas of the country. This genotype was not unexpected given the geographic location of the outbreak. This lineage then expanded its range, moving into multiple islands of the Indian Ocean before arriving in India, where, for the first time (2006), the ECSA genotype was transmitted outside of Africa. The ECSA Indian Ocean lineage continued to move throughout Southeast Asia. The Asian genotype virus was also found to be circulating at

low levels in Asia, but this transmission was scarcely noticed, given the scope of the ECSA genotype spread. However, the Asian genotype moved to novel areas of the Western Pacific (New Caledonia and the Federated States of Micronesia) before subsequently being detected in the Caribbean late in 2013 (1).

Throughout the epidemic, the virus was transmitted by its urban vectors (subgenus *Aedes* (*Stegomyia*)). From the earliest urban outbreaks, the virus was primarily transmitted by *Ae. aegypti* mosquitoes, but recent activity has also been confirmed to be associated with *Ae. albopictus*, as CHIKV outbreaks have

<sup>1</sup> Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, Fort Collins, CO, United States of America. Send correspondence to: Ann M. Powers, APowers@cdc.gov

been documented in places with no presence of the historical primary vector, such as Italy (2). In addition, other *Ae. (Stg.)* vectors (e.g., *Ae. hensilli*) have sustained outbreaks in areas where these species are prominent.

In anticipation of the virus reaching the Americas, there was considerable concern about the ability of local populations of mosquitoes to vector the introduced virus. Because the only *Ae. (Stg.)* species known to be in the Americas are *Ae. aegypti* and *Ae. albopictus*, a number of studies were undertaken to assess the vector competence of both species (3–7). Typically, both species were found to be readily infected by and competent vectors for either an ECSA strain or the introduced Asian genotype strain. However, as with most artificial infection studies, a high dose of virus (~6 log<sub>10</sub> plaque-forming units per mL (pfu/mL)) was usually used to infect the mosquitoes. The goal was to determine the minimum infection rate for each species. This information would allow for estimation of the length of time a viremic individual would be infectious. Because CHIKV-infected individuals have been estimated to have detectable levels of viremia for at least seven days (8), understanding the smallest dose needed to infect humans would provide significant public health preparedness information.

## MATERIALS AND METHODS

### Virus isolates

The viruses used for laboratory mosquito infections were obtained from the Arbovirus Reference Collection at the U.S. Centers for Disease Control and Prevention (CDC) (Fort Collins, Colorado, United States). CHIKV strain BVI 99660 was obtained from human serum samples from locally transmitted cases in the British Virgin Islands in 2014.

### Laboratory mosquito infections

Three- to four-day-old adult *Ae. aegypti* collected in Puerto Rico in 2015 (“PR”) and *Ae. albopictus* collected in Lake Charles, Louisiana, United States, in 1990 (“LC”) were fed on blood meals containing CHIKV strain BVI 99660 at various dilutions. The blood meals contained equal parts of virus, fetal bovine serum (FBS) with 10% sucrose, and sheep blood washed with phosphate-buffered saline

and packed by centrifugation. A Hemotek feeding system (Discovery Workshops, Accrington, United Kingdom) was used to deliver the blood meal to the mosquitoes for 1 hour at 37°C. The fully engorged females were collected and placed into a humidified environmental chamber and held at 28°C for 8 or 12 days until processing. The input virus titer for the blood meal titer was determined using a plaque assay.

After the intrinsic incubation period, the mosquitoes were cold-anesthetized and decapitated and each head and body placed into separate 1.7 mL tubes. A 450 µL aliquot comprised of 400 µL of Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% FBS, 100 U/mL of penicillin and streptomycin, and 1 U/mL of fungizone and gentamycin was added to each tube, and the sample was homogenized using a micropestle. The supernatant was clarified by filtration through a 0.2 µm syringe filter and stored at –70°C until use (9). Filtrates were tested for cytopathic effect (CPE) on Vero cells held at 37°C with 5% CO<sub>2</sub> for five days. A CPE-positive mosquito abdomen indicated a midgut infection whereas a CPE-positive mosquito head indicated a disseminated viral infection. The percent infected (proportion infected in a cohort, or prevalence) was calculated as the number of CPE-positive bodies out of the total number of bodies processed. The percent disseminated (proportion of samples in which the virus had been disseminated) was calculated as the number of CPE-positive heads out of the total number of CPE-positive bodies.

Saliva was collected before dissection from 20 mosquitoes per experiment. Mosquitoes were allowed to salivate into a glass capillary tube charged with 5 µL of Cargille type B immersion oil (Cargille Laboratories, Cedar Grove, New Jersey, United States) for 1 hour (10). The oil-filled end of the tube was broken off into the 1.7 mL tube containing the 450 µL of the DMEM solution, and the tubes were centrifuged at 4 500 × g for 5 minutes. Saliva samples were stored at –80°C until RNA extraction was performed.

### Viral nucleic acid extraction and detection

Viral RNA was isolated using the QIAamp Viral RNA protocol (QIAGEN Inc., Valencia, California, United States).

Total RNA was extracted from 100 µL of mosquito homogenate or from the saliva and eluted from the kit columns using 60 µL of elution buffer. The RNA was stored at –70°C until use.

Real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR) was used to detect and quantify CHIKV nucleic acid from mosquito saliva. The previously described chikungunya virus-specific primer and probe sets were used (11). The qRT-PCR assays were performed using the QuantiTect Probe RT-PCR reagent kit (QIAGEN Inc.). Briefly, a 50 µL total reaction volume consisted of kit components, 10 µL of RNA, 400 nanomolar (nM) of each primer, and 150 nM of probe. The reactions were subjected to 45 cycles of amplification in an iQ5 Real-Time PCR Detection System (Bio-Rad, Hercules, California) following the manufacturer’s protocol. The detection limit for CHIKV was found using the previously described techniques (12) and was cycle threshold (Ct) 38.0, which is equivalent to approximately 1.0 pfu/mL. In addition, each qRT-PCR run included standards to generate a quantitative RNA curve. The standard curve was completed by serially diluting the virus stock and extracting the RNA from each dilution, according to the previously mentioned RNA extraction protocol, while simultaneously titrating each dilution in a standard plaque assay. A curve correlation coefficient of ≥ 0.950 and a 90%–100% PCR efficiency was used to validate each detection assay.

## RESULTS

Infection of both *Ae. aegypti* (PR) and *Ae. albopictus* (LC) occurred with any dose > 3 log<sub>10</sub> pfu/mL of the Asian genotype virus input. The minimum dose infecting *Ae. aegypti* and *Ae. albopictus* where virus could be detected in the saliva of at least one mosquito is between 4.9–5.3 log<sub>10</sub> pfu/mL and 2.9–3.9 log<sub>10</sub> pfu/mL respectively (Table 1). The maximum percent infected (based on CPE analysis) for *Ae. aegypti* mosquitoes was 95.8% (with a dose of 6.3 log<sub>10</sub> pfu/mL); at the lowest dose demonstrating transmission (5.3 log<sub>10</sub> pfu/mL) the percent infected was 60.0%. A lower virus exposure dose was observed for *Ae. albopictus* mosquitoes, with a dose as low as 3.9 log<sub>10</sub> pfu/mL of CHIKV in that species resulting in a 35.0% infection rate, and the maximum dose evaluated (5.7 log<sub>10</sub> pfu/mL) resulting in an 84.6% infection rate. In both species,

**TABLE 1. Percent infection of bodies and heads of two strains of *Aedes* mosquito (based on cytopathic effect (CPE) analysis) and virus quantitation in saliva after exposure to CHIKV strain BVI 99660,<sup>a,b</sup> Fort Collins, Colorado, United States, 2016**

Mosquito strain <sup>c</sup>	Number tested	Infecting dose (log <sub>10</sub> pfu <sup>d</sup> /mL)	CPE analysis		Virus quantitation in saliva	
			Body (%)	Head (%)	Pos <sup>e</sup> (%)	Titer (pfu)
<i>Ae. aegypti</i> (PR)	36	4.6	13.9	80.0	0	0
	28	4.9	14.3	75.0	0	0
	10	5.3	60.0	100.0	33.3	505
	37	5.6	73.3	100.0	53.3	935
	36	6.1	91.7	100.0	75.0	5 000
	24	6.3	95.8	100.0	36.8	3 545
<i>Ae. albopictus</i> (LC)	30	2.9	0	0	0	0
	40	3.9	35.0	92.9	66.7	1 921
	32	4.6	71.9	95.7	66.7	2 334
	39	5.7	84.6	97.0	94.4	39 100

<sup>a</sup> Chikungunya virus (human serum sample collected in the British Virgin Islands in 2014).

<sup>b</sup> All results are for Day 8 post-exposure except the 6.3 log<sub>10</sub> dose, which was for Day 12 post-exposure.

<sup>c</sup> *Ae. aegypti* collected in Puerto Rico in 2015 ("PR") and *Ae. albopictus* collected in Lake Charles, Louisiana, United States, in 1990 ("LC") (3- to 4-day-old adults).

<sup>d</sup> Plaque-forming units.

<sup>e</sup> "Positive" (proportion of CPE-positive heads with saliva positive for the virus based on quantitative reverse transcription polymerase chain reaction (qRT-PCR)).

when infection occurred, virtually all mosquitoes developed a disseminated infection. This was detected even when infection rates were as low as 13.9%. In all cases, for both mosquito species, the lowest dissemination rate detected was 75.0% (in *Ae. aegypti*, with a blood meal titer of 4.9 log<sub>10</sub> pfu/mL).

Dissemination occurred with nearly all infections in both species, and the percentage of mosquitoes transmitting the virus increased with higher virus titers in the blood meal. In *Ae. aegypti*, when no transmission was detected, the proportion infected was less than 15%. Transmission in *Ae. albopictus* occurred at a lower dose than *Ae. aegypti* (3.9 log<sub>10</sub> pfu/mL versus 5.3 log<sub>10</sub> pfu/mL respectively). However, transmission rates reached at least 75% in both species. The maximum titer of CHIKV in saliva was 5 000 pfu after exposure to 6.1 log<sub>10</sub> pfu/mL of virus for *Ae. aegypti* and 39 100 pfu after exposure to 5.7 log<sub>10</sub> pfu/mL for *Ae. albopictus* mosquitoes. However, variation of the viral titer in the saliva was not proportional to the input dose; all saliva samples contained a 5x10<sup>2</sup>–5x10<sup>3</sup> viral titer. Variation in the saliva virus titer was only found at the highest dose in *Ae. albopictus*, where a titer of 4x10<sup>4</sup> was found.

## DISCUSSION

Understanding the ability of a mosquito species to be infected by and transmit a virus is a critical element in gauging the epidemiological risk of local populations. With the introduction of CHIKV in the Americas with a strain of virus from, unexpectedly, the Asian genotype, it was critical

to assess how populations of both known vectors, *Ae. aegypti* and *Ae. albopictus*, would be able to transmit CHIKV. Historically, various populations of both species have been assessed for infection with CHIKV of various lineages (13, 14). These early studies indicated that both vector species would serve as competent vectors, but *Ae. albopictus* was often found to be more competent in laboratory studies. This was an interesting and unexpected finding at the time, because (until 2006) no CHIKV outbreak had ever been documented as associated with *Ae. Albopictus*.

In preparing for the entry of CHIKV into the Americas, a number of studies sought to evaluate American populations of *Ae. aegypti* and *Ae. albopictus* for infectivity with the anticipated lineage of CHIKV derived from the Indian Ocean lineage of the ECSA genotype. One study examined *Ae. albopictus* from the Eastern United States using a range of blood meals (5.3x10<sup>3</sup>–1.5x10<sup>5</sup> pfu/mL) and determined that the percent infected ranged from 31% to 86% (6). The study also examined transmission rates, which never exceeded 50%. A similar single-species study focused on *Ae. aegypti* from the French West Indies and French Guiana (where the virus was first established in the Americas) (4). The study used local populations of *Ae. aegypti* with only high titers (6.0 or 7.5 log<sub>10</sub> pfu/mL) of the infecting virus (the ECSA genotype). Infection rates were 38%–62% for the 6 log dose and 89%–100% for the higher dose. Another study looked at infection in both *Ae. albopictus* and *Ae. aegypti* from the U.S. state of Florida (F1) and other

(long-established) colonies (including the LC strain used in this study) using blood meals with titers of approximately 6 log<sub>10</sub> pfu/mL (5). All mosquito species and virus strains tested had infection rates greater than 90% at seven days post-exposure. Interestingly, the study also examined the timing of the dissemination of the virus within the mosquitoes and found that both strains of *Ae. albopictus* (Florida and LC) disseminated equally well and more efficiently than either *Ae. aegypti* strain. However, no transmission rates were determined in the study, and only high infecting virus doses were used. In addition, all of these studies used ECSA viral lineage strains, which may have resulted in properties very different than those in mosquitoes infected with an Asian genotype lineage.

One very comprehensive study examined 35 populations of *Ae. albopictus* and *Ae. aegypti* from 10 countries in the Americas (ranging geographically from Argentina to the United States) to determine dissemination and transmission rates using both ECSA strains and an Asian genotype strain (7). Overall, high dissemination rates were found in all *Ae. albopictus* and *Ae. aegypti* populations tested; only four had dissemination rates less than 83% at Day 7 post-exposure. All *Ae. albopictus* and *Ae. aegypti* populations exposed to the Asian genotype strain had infection rates of at least 90% but the infecting blood meal dose was extremely high (7.5 log<sub>10</sub> pfu/mL). This was interesting given that no infection assessment was performed directly but the high dissemination rates indirectly suggest the infection rate was equally high.

The transmission rates were found to vary significantly with the population examined. Overall, *Ae. albopictus* infected with the Asian genotype strain had lower transmission rates than corresponding populations of *Ae. aegypti*. The study also included a transmission efficiency element that suggested the possibility of the presence of a salivary gland escape barrier, but the very high infecting dose may have biased overall infection and dissemination values.

In this study, the goal was to assess U.S. mosquito populations of *Ae. albopictus* and *Ae. aegypti* using a relevant strain of virus (the Asian genotype) at a range of doses to determine the minimum infectious dose. Like the earlier studies, high rates of dissemination were found, virtually independent of blood meal virus titer or percentage of mosquitoes infected. Basically, if the mosquitoes became infected, the virus spread throughout the mosquito population, suggesting no salivary gland infection barriers exist in either *Ae. albopictus* or *Ae. aegypti*. In contrast, infection rates were linked to the blood meal virus titer, indicating that a midgut infection barrier is present, most likely in both species but more pronounced in *Ae. aegypti*. Transmission rates in the two species also increased with higher blood meal virus titers, which was somewhat unexpected given that the dissemination rates in both species, which were high, did not correlate with infecting dose. The variation in the transmission rates suggests the

presence of a salivary gland escape barrier, as has been previously speculated.

This study showed that infecting titers at least as low as  $3.9 \log_{10}$  pfu/mL (in *Ae. albopictus*) and  $5.3 \log_{10}$  pfu/mL (in *Ae. aegypti*) could lead to transmission, indicating the infectious period of a viremic individual is proportionally longer than expected. Epidemiology studies have shown that viremia in infected humans can be detected at up to 10 days post-illness onset, with titers of at least  $10^{3.9}$  pfu/mL at every time point tested (8). Those findings, combined with the results of this study, suggest that the vast majority of individuals could infect mosquitoes during most of their viremic period (which typically lasts for approximately one week). This may be a major epidemiological factor in the high attack rates found in areas where the virus is newly introduced.

### Limitations

This study had some limitations, such as not using a range of different mosquito populations, and the use of long-colonized strains (although previous work has shown the latter trait is not a contributing factor in infection and dissemination rates in *Ae. albopictus* LC).

### Conclusions

This study has shown that acutely ill individuals are highly infectious to

mosquitoes for extended periods of time. Therefore, in addition to conventional measures to reduce the risk of mosquito bites population-wide, such as larval source reduction and use of larvicidal products, the use of additional measures to prevent infected individuals from getting bitten by mosquitoes, which could lead to further infections, are necessary for public health protection during active transmission events. Additional measures could include the use of mosquito repellents; long sleeves and/or pants; and bed nets (particularly during daytime hours) by already-infected individuals. Adding these additional measures to interventions may help control clusters of infections and reduce the scope of the overall outbreak.

**Acknowledgments.** The authors thank Roberto Barrera and John-Paul Mutebi of the U.S. Centers for Disease Control and Prevention (CDC) for providing the mosquitoes used in this study.

**Conflicts of interest.** None.

**Disclaimer.** Authors hold sole responsibility for the views expressed in the manuscript, which may not necessarily reflect the opinion or policy of the CDC, the *RPSP/PAJPH*, or the Pan American Health Organization (PAHO).

## REFERENCES

1. Powers AM. Risks to the Americas associated with the continued expansion of chikungunya virus. *J Gen Virol.* 2015;96 (Pt 1):1–5.
2. Bonilauri P, Bellini R, Calzolari M, Angelini R, Venturi L, Fallacara F, et al. Chikungunya virus in *Aedes albopictus*, Italy. *Emerg Infect Dis.* 2008;14(5):852–4.
3. Pesko K, Westbrook CJ, Mores CN, Lounibos LP, Reiskind MH. Effects of infectious virus dose and bloodmeal delivery method on susceptibility of *Aedes aegypti* and *Aedes albopictus* to chikungunya virus. *J Med Entomol.* 2009;46(2):395–9.
4. Girod R, Gaborit P, Marrama L, Etienne M, Ramdini C, Rakotoarivony I, et al. High susceptibility to Chikungunya virus of *Aedes aegypti* from the French West Indies and French Guiana. *Trop Med Int Health.* 2011;16(1):134–9.
5. Reiskind MH, Pesko K, Westbrook CJ, Mores CN. Susceptibility of Florida mosquitoes to infection with chikungunya virus. *Am J Trop Med Hyg.* 2008;78(3):422–5.
6. McTighe SP, Vaidyanathan R. Vector competence of *Aedes albopictus* from Virginia and Georgia for chikungunya virus isolated in the Comoros Islands, 2005. *Vector Borne Zoonotic Dis.* 2012;12(10):867–71.
7. Vega-Rúa A, Zouache K, Girod R, Failloux AB, Lourenço-de-Oliveira R. High level of vector competence of *Aedes aegypti* and *Aedes albopictus* from ten American countries as a crucial factor in the spread of Chikungunya virus. *J Virol.* 2014;88(11):6294–306.
8. Lanciotti RS, Kosoy OL, Laven JJ, Panella AJ, Velez JO, Lambert AJ, et al. Chikungunya virus in US travelers returning from India, 2006. *Emerg Infect Dis.* 2007;13(5):764–7.
9. Mossel EC, Ledermann JP, Phillips AT, Borland EM, Powers AM, Olson KE. Molecular determinants of mouse neurovirulence and mosquito infection for Western equine encephalitis virus. *PLoS One.* 2013;8(3):e60427.
10. Beaty BJ, Aitken TH. In vitro transmission of yellow fever virus by geographic strains of *Aedes aegypti*. *Mosquito News.* 1979;39(2):332–8.
11. Partidos CD, Weger J, Brewoo J, Seymour R, Borland EM, Ledermann JP, et al. Probing the attenuation and protective efficacy of a candidate chikungunya virus vaccine in mice with compromised interferon (IFN) signaling. *Vaccine.* 2011;29(16):3067–73.
12. Linnen JM, Vinelli E, Sabino EC, Tobler LH, Hyland C, Lee TH, et al. Dengue viremia in blood donors from Honduras, Brazil, and Australia. *Transfusion.* 2008;48(7):1355–62.
13. Tesh RB, Gubler DJ, Rosen L. Variation among geographic strains of *Aedes albopictus* in susceptibility to infection with chikungunya virus. *Am J Trop Med Hyg.* 1976;25(2):326–35.
14. Turell MJ, Beaman JR, Tammariello RF. Susceptibility of selected strains of *Aedes aegypti* and *Aedes albopictus* (Diptera: Culicidae) to chikungunya virus. *J Med Entomol.* 1992;29(1):49–53.

Manuscript received 1 November 2015. Revised version accepted for publication on 8 July 2016.



---

**Dosis infecciosa mínima del virus del chikungunya en los mosquitos *Aedes aegypti* y *Ae. albopictus***

**RESUMEN**

Comprender la capacidad del virus del chikungunya (CHIKV) de ser transmitido por los vectores del género *Aedes* en la Región de las Américas es fundamental para evaluar el riesgo epidemiológico. Un elemento que debe tenerse en cuenta es la dosis infecciosa mínima de virus que posibilita la transmisión después del período de incubación extrínseco. El objetivo de este estudio ha sido determinar la tasa de infección mínima para las dos especies del género *Aedes* estudiadas. Los resultados indican que bastan dosis de tan solo 3,9 log<sub>10</sub> unidades formadoras de placas por mililitro (ufp/ml) de una cepa de CHIKV del genotipo asiático para que se produzca la transmisión por *Ae. albopictus*, en tanto que para la transmisión por *Ae. aegypti* se necesitan dosis de al menos 5,3 log<sub>10</sub> ufp/ml de la misma cepa. Estas dosis bajas indican que las personas infectadas podrían conservar el potencial infeccioso prácticamente durante todo el período de viremia y, por consiguiente, a fin de prevenir más casos, habría que tomar medidas para impedir que reciban picaduras de mosquitos durante ese período.

**Palabras clave**

*Aedes*; virus chikungunya; epidemiología; Américas.

---